COMPOSITION OF TUMOR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE FOR THE TREATMENT OF GLIOBLASTOMA (GBM) AND OTHER CANCERS

• US 20130309193A1
• Filed: 03/15/2013
• Published: 11/21/2013
• Est. Priority Date: 10/01/2008
• Status: Active Grant

• Current Assignee: Immatics Biotechnologies GmbH (Immatics NV)
• Original Assignee: Immatics Biotechnologies GmbH (Immatics NV)
• Inventors: WEINSCHENK, Toni, SCHOOR, Oliver, TRAUTWEIN, Claudia, HILF, Norbert, SINGH, Harpreet, WALTER, Steffan
• Granted Patent: US 8,895,514 B2
• Time in Patent Office: Days
• US Class Current: 424/85.1
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: A61K 2039/55511 Organic adjuvants
• CPC Class Codes: A61K 2039/55516 Proteins; Peptides
• CPC Class Codes: A61K 2039/55522 Cytokines; Lymphokines; Interferons
• CPC Class Codes: A61K 2039/55561 CpG containing adjuvants; Oligonucleotide containing adjuvants
• CPC Class Codes: A61K 2039/55588 Adjuvants of undefined constitution
• CPC Class Codes: A61K 2039/572 cytotoxic response
• CPC Class Codes: A61K 2039/605 MHC molecules or ligands thereof
• CPC Class Codes: A61K 2039/6081 Albumin; Keyhole limpet haemocyanin [KLH]
• CPC Class Codes: A61K 2039/6093 Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
• CPC Class Codes: A61K 35/17 Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes when activated by a specific antigen A61K39/00
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/0011 Cancer antigens
• CPC Class Codes: A61K 39/4611 T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
• CPC Class Codes: A61K 39/4644 Cancer antigens
• CPC Class Codes: A61M 5/002 Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics needle protection, e.g. caps, A61M5/3202; for sharps A61B50/3001
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/08 : of the prostate
• CPC Class Codes: A61P 13/12 : of the kidneys
• CPC Class Codes: A61P 15/00 : Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 17/00 : Drugs for dermatological disorders
• CPC Class Codes: A61P 25/00 : Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/02 : Ophthalmic agents
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: A61P 35/02 : specific for leukemia
• CPC Class Codes: A61P 37/04 : Immunostimulants
• CPC Class Codes: C07K 14/70539 : MHC-molecules, e.g. HLA-molecules
• CPC Class Codes: C07K 2319/00 : Fusion polypeptide
• CPC Class Codes: C07K 2319/40 : containing a tag for immunodetection, or an epitope for immunisation
• CPC Class Codes: C07K 7/06 : having 5 to 11 amino acids
• CPC Class Codes: C07K 7/08 : having 12 to 20 amino acids gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68
• CPC Class Codes: C12N 2501/50 : Cell markers; Cell surface determinants
• CPC Class Codes: C12N 5/0638 : Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
• CPC Class Codes: C12N 5/0639 : Dendritic cells, e.g. Langherhans cells in the epidermis
• CPC Class Codes: G01N 33/57492 : involving compounds localized on the membrane of tumor or cancer cells
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gliomas.

Claims

1. A pharmaceutical composition, comprising:

(i) at least two immunogenic peptides from 8 to 100 amino acids in length, one of said peptides comprising an amino acid sequence that is at least 80% identical to a sequence selected from the group consisting of SEQ ID NO;

4, SEQ ID NO;

5, SEQ ID NO;

7, and SEQ ID NO;

8, and (ii) a pharmaceutically acceptable carrier.

2. The pharmaceutical composition according to claim 1, wherein another of said peptides comprises an amino acid sequence that is at least 80% identical to a sequence selected from the group consisting of SEQ ID NO:

9 to SEQ ID NO;

20.

3. The pharmaceutical composition according claim 2, wherein the second peptide is selected from the group consisting of SEQ ID NO:

1 to SEQ ID NO;

20.

4. The pharmaceutical composition according to claim 1, wherein at least one of the at least two peptides includes non-peptide bonds.

5. The pharmaceutical composition of claim 1, where the first peptide comprises a sequence selected from the group consisting of SEQ ID NO:

4, SEQ ID NO;

5, SEQ ID NO;

7, and SEQ ID NO;

8.

6. The pharmaceutical composition of claim 1, wherein the first peptide consists of a core sequence consisting of a sequence selected from the group consisting of SEQ ID NO:

4, SEQ ID NO;

5, SEQ ID NO;

7, and SEQ ID NO;

8 with extensions of 1 to 10 amino acids on the C-terminal and/or the N-terminal of the core sequence.

7. The pharmaceutical composition of claim 1, wherein the first peptide consists of a sequence selected from the group consisting of SEQ ID NO:

4, SEQ ID NO;

5, SEQ ID NO;

7, and SEQ ID NO;

8.

8. The pharmaceutical composition according to claim 1, further comprising at least one suitable adjuvant.

9. The pharmaceutical composition according to claim 8, wherein the adjuvant is selected from the group consisting of colony-stimulating factors, GM-CSF, imiquimod, and resiquimod.

10. The pharmaceutical composition according to claim 8, comprising two to four adjuvants.

11. The pharmaceutical composition according to claim 10, wherein least two of the adjuvants are selected from the group consisting of CP-870,893, CpG7909, GM-CSF, imiquimod, and resiquimod.

12. The pharmaceutical composition according to claim 1, additionally comprising at least one antigen presenting cell.

13. The pharmaceutical composition according to claim 12, wherein the antigen presenting cell is a dendritic cell.

14. The pharmaceutical composition according to claim 12, wherein the at least one antigen presenting cell:

a) is pulsed or loaded with the peptide;

or

b) comprises an expression construct encoding the peptide.

15. The pharmaceutical composition of claim 1, wherein the composition is administered intravenously, intra-arterially, intra-peritoneally, intramuscularly, intradermally, intratumorally, orally, dermally, nasally, buccally, rectally, vaginally, by inhalation, or by topical administration.

16. A method for treating and/or preventing a cancer in a patient, the method comprising administering to the patient a therapeutically effective amount of the pharmaceutical composition of claim 1.

17. The method according to claim 16, wherein the pharmaceutical composition is an anti-cancer vaccine.

18. The method of claim 17, wherein the cancer is one or more of cancer of the buccal cavity or pharynx, cancer of the digestive tract, cancer of the colon, rectum, or anus, cancer of the respiratory tract, breast cancer, cancer of the cervix uteri, vagina, or vulva, cancer of the uterine corpus or ovary, cancer of the male genital tract, cancer of the urinary tract, bone or soft tissue cancer, Kaposi sarcoma, melanoma of the skin, ocular melanoma, non-melanoma eye cancer, cancer of the brain and central nervous system, cancer of the thyroid and other endocrine glands, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, myeloma, renal cancer, colorectal cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, gastric cancer, GIST or glioblastoma.

19. The method according to claim 18, wherein the cancer is colorectal cancer.